Short-term observation of direct oral anticoagulant use in an atrial fibrillation patient with high bleeding risk and kidney transplant: a case report

Kidney transplant （KTx） is considered to be the best treatment for end-stage renal diseases compared with hemodialysis or peritoneal dialysis, because it significantly improves renal function, reduces cardiovascular events and mortality, enhances quality of life and prolongs life expectancy. [1,2] Atrial fibrillation （AF） is frequently coexistent with KTx, and a higher risk will occur in KTx recipients with AF compared with those aren’t with AF. [3] Patients with AF are at risk of stroke, systemic emboli and death. It is recommended that high-risk AF patients should use oral anticoagulants for preventive treatment. Direct oral anticoagulants （DOACs）, including dabigatran,